The landscape of drug development is constantly evolving, fueled by groundbreaking scientific advancements. While genetics has played a central role in understanding diseases, proteomics – the study of proteins – provides a more comprehensive picture of disease phenotypes and mechanisms. Proteins act as intermediate phenotypes, bridging the gap between genetic associations and tangible disease pathology. […]
View Blog
The field of proteomics has evolved significantly in the last decade, with several technologies now available to assay protein biomarkers in clinical studies. In this article, we compare three popular approaches for proteomics – mass spectrometry, ELISA, and the Olink® Proximity Extension Assay (PEA) – and highlight their strengths and limitations. Mass Spectrometry Assays based on mass spectrometry […]
View Blog
The development of scalable and sensitive technologies, such as next generation sequencing (NGS) and quantitative PCR (qPCR), has revolutionized genomics by enabling nucleic acids of almost any sequence to be amplified and quantified with relative ease using standard chemistries, revealing contextual insights into the complete genome and transcriptome. Proteins, on the other hand, the study […]
View Blog